That was something that was know for decades. They don't know exactly what role serotonin plays in depression. Within the last few months they just published a paper about how they have been able to for the first time have been able to measure serotonin in the human brain. It even showed that people who were depressed showed lower levels of serotonin. This will bring new research to find exactly the role of serotonin plays in depression and hopefully develop more effective medications. That study you referred to also left out the fact there are other neurotransmitters involved including norepinephrine and dopamine. Ruoxinlin works on all 3 neurotransmitters. The only medication to do this so far has been nefazodone (weak SNDRI due to low effect on dopamine).
It is referenced in this article as Toludesvenlafaxine. This was just published. It has been available in China since last November and is expected to be available in the U.S. in 2024. It will be the first full SNDRI available on the market.
That-Group-7347 OP t1_jbqicn1 wrote
Reply to comment by joxeloj in Comprehensive review and trial results of upcoming antidepressant Ruoxinlin (ansofaxine) by That-Group-7347
It says in here it is a new method to measure the release on the brain. https://scitechdaily.com/serotonin-deficiency-directly-linked-with-depression-in-groundbreaking-study/